Author
University of California, Los AngelesORCID 0000-0001-5119-8721Unclaimed ORCID profile · follow to get notified of new preprints
5 papers
Recent·Most cited
María Sol Recouvreux, Kathleen Trang, Alexandra Smick…·Sandra Oršulić
This study uses spatial transcriptomics to analyze fallopian tube lesions and identifies immune and stromal changes associated with early ovarian cancer development.
Angelina Flores, Jennifer Soto, Navjot Kaur Gill…·Amy C. Rowat
The paper screens compounds to identify mechanical mediators by measuring cell deformability, finding NUDT5 as a key mediator in ovarian cancer.
Kranthi Kumar Chougoni, Jacqueline L. West, Nicholette St. Martin…·Steven R. Grossman
The paper shows that combining CtBP inhibitors with NAD synthesis inhibitors enhances cell death and inhibits growth of high-grade serous ovarian carcinoma.
Angela M. Schab, Amanda J. Compadre, Rikki Drexler…·Mary Margaret Mullen
This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.
Elizabeth R. Woodruff, Courtney A. Bailey, Francis To…·Zachary L. Watson
This study shows that ablating hematopoietic stem cell-derived adipocytes reduces tumor burden in mouse models of high-grade serous carcinoma through metabolic and immune mechanisms.